JAK/STAT in Leukemia: a Clinical Update

Overview

Journal Mol Cancer

Publisher Biomed Central

Specialties Molecular Biology
Oncology

Date 2024 Jan 25

PMID 38273387

Authors

Dong Liang

Qiaoli Wang

Wenbiao Zhang

Hailin Tang

Cailu Song

Zhimin Yan

Yang Liang

Hua Wang

Affiliations

Soon will be listed here.

Abstract

Over the past three decades, considerable efforts have been expended on understanding the Janus kinase/signal transducer and activator of transcription (JAK/STAT) signaling pathway in leukemia, following the identification of the JAK2V617F mutation in myeloproliferative neoplasms (MPNs). The aim of this review is to summarize the latest progress in our understanding of the involvement of the JAK/STAT signaling pathway in the development of leukemia. We also attempt to provide insights into the current use of JAK/STAT inhibitors in leukemia therapy and explore pertinent clinical trials in this field.

Citing Articles

Identification of STAT3 phosphorylation inhibitors using generative deep learning, virtual screening, molecular dynamics simulations, and biological evaluation for non-small cell lung cancer therapy.

Cai W, Jiang B, Yin Y, Ma L, Li T, Chen J Mol Divers. 2024; .

PMID: 39715975 DOI: 10.1007/s11030-024-11067-5.

Targeting the JAK-STAT pathway in colorectal cancer: mechanisms, clinical implications, and therapeutic potential.

Li P, Huang D Front Cell Dev Biol. 2024; 12:1507621.

PMID: 39659524 PMC: 11628519. DOI: 10.3389/fcell.2024.1507621.

Clonal evolution defines risk stratification for central nervous system leukemia in adult acute lymphoblastic leukemia.

Li J, Chen J, Wang Q, Ou J, Huang Z, Deng S Ann Hematol. 2024; 103(12):5759-5767.

PMID: 39609281 DOI: 10.1007/s00277-024-06116-w.

The Role of the JAK-STAT Pathway in Childhood B-Cell Acute Lymphoblastic Leukemia.

Zietara K, Wroblewska K, Zajaczkowska M, Taczala J, Lejman M Int J Mol Sci. 2024; 25(13).

PMID: 38999955 PMC: 11241568. DOI: 10.3390/ijms25136844.

Hallmarks of cancer resistance.

Tufail M, Hu J, Liang J, He C, Wan W, Huang Y iScience. 2024; 27(6):109979.

PMID: 38832007 PMC: 11145355. DOI: 10.1016/j.isci.2024.109979.

References

Dudka W, Hoser G, Mondal S, Turos-Korgul L, Swatler J, Kusio-Kobialka M . Targeting integrated stress response with ISRIB combined with imatinib treatment attenuates RAS/RAF/MAPK and STAT5 signaling and eradicates chronic myeloid leukemia cells. BMC Cancer. 2022; 22(1):1254. PMC: 9719211. DOI: 10.1186/s12885-022-10289-w. View

Sueur G, Boutet A, Gotanegre M, Mas V, Besson A, Manenti S . STAT5-dependent regulation of CDC25A by miR-16 controls proliferation and differentiation in FLT3-ITD acute myeloid leukemia. Sci Rep. 2020; 10(1):1906. PMC: 7002454. DOI: 10.1038/s41598-020-58651-x. View

Hoey T, Schindler U . STAT structure and function in signaling. Curr Opin Genet Dev. 1998; 8(5):582-7. DOI: 10.1016/s0959-437x(98)80015-4. View

Kollmann S, Grundschober E, Maurer B, Warsch W, Grausenburger R, Edlinger L . Twins with different personalities: STAT5B-but not STAT5A-has a key role in BCR/ABL-induced leukemia. Leukemia. 2019; 33(7):1583-1597. PMC: 6755975. DOI: 10.1038/s41375-018-0369-5. View

Kiel M, Velusamy T, Rolland D, Sahasrabuddhe A, Chung F, Bailey N . Integrated genomic sequencing reveals mutational landscape of T-cell prolymphocytic leukemia. Blood. 2014; 124(9):1460-72. PMC: 4148768. DOI: 10.1182/blood-2014-03-559542. View

Hallek M, Fischer K, Fingerle-Rowson G, Fink A, Busch R, Mayer J . Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010; 376(9747):1164-74. DOI: 10.1016/S0140-6736(10)61381-5. View

Hubbard J, Grothey A . Napabucasin: An Update on the First-in-Class Cancer Stemness Inhibitor. Drugs. 2017; 77(10):1091-1103. DOI: 10.1007/s40265-017-0759-4. View

Gouilleux-Gruart V, Gouilleux F, Desaint C, Claisse J, Capiod J, Delobel J . STAT-related transcription factors are constitutively activated in peripheral blood cells from acute leukemia patients. Blood. 1996; 87(5):1692-7. View

Seif F, Khoshmirsafa M, Aazami H, Mohsenzadegan M, Sedighi G, Bahar M . The role of JAK-STAT signaling pathway and its regulators in the fate of T helper cells. Cell Commun Signal. 2017; 15(1):23. PMC: 5480189. DOI: 10.1186/s12964-017-0177-y. View

10.

Benyoucef A, Haigh K, Cuddihy A, Haigh J . JAK/BCL2 inhibition acts synergistically with LSD1 inhibitors to selectively target ETP-ALL. Leukemia. 2022; 36(12):2802-2816. PMC: 9712096. DOI: 10.1038/s41375-022-01716-9. View

11.

Santos S, Monni R, Bouchaert I, Bernard O, Gisselbrecht S, Gouilleux F . Involvement of the NF-kappaB pathway in the transforming properties of the TEL-Jak2 leukemogenic fusion protein. FEBS Lett. 2001; 497(2-3):148-52. DOI: 10.1016/s0014-5793(01)02452-8. View

12.

Verstovsek S, Odenike O, Singer J, Granston T, Al-Fayoumi S, Deeg H . Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies. J Hematol Oncol. 2016; 9(1):137. PMC: 5146859. DOI: 10.1186/s13045-016-0367-x. View

13.

Rai K, Peterson B, Appelbaum F, Kolitz J, Elias L, Shepherd L . Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med. 2000; 343(24):1750-7. DOI: 10.1056/NEJM200012143432402. View

14.

Ohanian M, Leventaki V, Verstovsek S, Estrov Z, Lin P, Yin C . Acute lymphoblastic leukemia arising in post-polycythemic myelofibrosis: a rare entity. Leuk Lymphoma. 2012; 53(9):1839-41. PMC: 4120044. DOI: 10.3109/10428194.2012.663916. View

15.

Griffiths E, Gore S, Hooker C, Mohammad H, McDevitt M, Smith B . Epigenetic differences in cytogenetically normal versus abnormal acute myeloid leukemia. Epigenetics. 2010; 5(7):590-600. PMC: 3052845. DOI: 10.4161/epi.5.7.12558. View

16.

Lee J, Kim Y, Soung Y, Han K, Kim S, Rhim H . The JAK2 V617F mutation in de novo acute myelogenous leukemias. Oncogene. 2005; 25(9):1434-6. DOI: 10.1038/sj.onc.1209163. View

17.

Frankson R, Yu Z, Bai Y, Li Q, Zhang R, Zhang Z . Therapeutic Targeting of Oncogenic Tyrosine Phosphatases. Cancer Res. 2017; 77(21):5701-5705. PMC: 5827927. DOI: 10.1158/0008-5472.CAN-17-1510. View

18.

Mansier O, Kilani B, Guitart A, Guy A, Gourdou-Latyszenok V, Marty C . Description of a knock-in mouse model of JAK2V617F MPN emerging from a minority of mutated hematopoietic stem cells. Blood. 2019; 134(26):2383-2387. DOI: 10.1182/blood.2019001163. View

19.

Jurado S, Fedl A, Jaritz M, Kostanova-Poliakova D, Malin S, Mullighan C . The PAX5-JAK2 translocation acts as dual-hit mutation that promotes aggressive B-cell leukemia via nuclear STAT5 activation. EMBO J. 2022; 41(7):e108397. PMC: 8982625. DOI: 10.15252/embj.2021108397. View

20.

Maurer B, Nivarthi H, Wingelhofer B, Pham H, Schlederer M, Suske T . High activation of STAT5A drives peripheral T-cell lymphoma and leukemia. Haematologica. 2019; 105(2):435-447. PMC: 7012494. DOI: 10.3324/haematol.2019.216986. View